Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-labeled anti-BCMA nanobody
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
18F-labeled anti-BCMA nanobody (specifically [18F]FPy-BCMA-Nb) is a radiolabeled single-domain antibody (nanobody) targeting B-cell maturation antigen (BCMA), developed by researchers at the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the University of Miami. It is designed as a high-contrast positron emission tomography (PET) imaging agent for the detection and monitoring of multiple myeloma, particularly for visualizing heterogeneous bone marrow involvement and minimal residual disease. The nanobody is conjugated to an [18F]fluoropyridine ([18F]FPy) prosthetic group, which provides a favorable pharmacokinetic profile characterized by rapid systemic clearance, minimal renal accumulation, and high tumor-to-background ratios. In preclinical studies, this imaging agent has been evaluated alongside a companion therapeutic counterpart labeled with iodine-131 ([131I]I-BCMA-Nb) as part of a theranostic platform for multiple myeloma.
- Other names
- [18F]FPy-BCMA-Nb18F-FPy-BCMA18F-FPy-BCMA Nb18F-FPy-BCMA-Nb18F-labeled BCMA nanobody
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on 18F-labeled anti-BCMA nanobody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-labeled anti-BCMA nanobody.